Vandetanib, cabozantinib, and sorafenib have inhibitory activity against FLT3 kinase along with growth inhibitory activity against acute myeloid leukemia cells with FLT3 mutation [21,22,23]. This evidence concerns the gene FLT3 and acute myeloid leukemia.